Meeting
2017 ASCO Annual Meeting
Characterisation of CCS1477: A novel small molecule inhibitor of p300/CBP for the treatment of castration resistant prostate cancer.
Authors
Neil Pegg
CellCentric Ltd, Cambridge, United Kingdom
Neil Pegg , Nigel Brooks , Jenny Worthington , Barbara Young , Amy Prosser , Jordan Lane , David Taddei , Richard Brown , Gareth Harbottle , Jonathan Shannon , Silvia Paoletta , Karen E. Knudsen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Tumor Biology
Track
Tumor Biology
Sub Track
New Targets and New Technologies
Citation
J Clin Oncol 35, 2017 (suppl; abstr 11590)
DOI
10.1200/JCO.2017.35.15_suppl.11590
Abstract #
11590
Poster Bd #
290
Abstract Disclosures
Similar Posters
Poster
2017 Genitourinary Cancers Symposium
A novel small molecule inhibitor of p300/CBP for the treatment of castration-resistant prostate cancer: Preclinical evaluation.
First Author: Nigel Brooks
Poster
2015 Genitourinary Cancers Symposium
Dual targeting of the androgen receptor and hypoxia-inducible factor-1α pathways to synergistically inhibit castrate-resistant prostate cancer.
First Author: William Douglas Figg
Poster
2023 ASCO Genitourinary Cancers Symposium
Association of emergent neuroendocrine prostate cancer detected by liquid biopsies with survival and treatment resistance.
First Author: Amy K Taylor
Poster
2019 ASCO Annual Meeting
Targeting the p300/CBP interactome through blockage of the CH1-domain triggers tumor regression in AR-positive and AR-negative xenograft models of castration-resistant prostate cancer (CRPC).
First Author: Valentino Cattori